Form 4: Denali Therapeutics Executive Alexander Schuth Sells Shares to Cover Tax Obligations

Alexander Schuth, COFO and Secretary of Denali Therapeutics, sold shares of common stock to cover tax obligations related to vested restricted stock units, according to a Form 4 filing.

Summary

• Alexander Schuth, COFO and Secretary of Denali Therapeutics, sold shares of the company's common stock on August 20 and 21, 2024.
• The sales were executed to satisfy tax obligations related to the settlement of previously vested restricted stock units.
• On August 20, 2024, Schuth sold 2,453 shares at $23.79 per share and 3,353 shares at a weighted average price of $23.54 (ranging from $23.38 to $23.72).
• On August 21, 2024, Schuth sold 2,547 shares at a weighted average price of $24.78 (ranging from $24.19 to $25.07).
• Following these transactions, Schuth directly owns 178,066 shares of Denali Therapeutics common stock, which includes 118,810 unvested RSUs.
• He also indirectly owns 523,749 shares through The Schuth Family Trust U/A DTD 06/05/2017, where he serves as trustee.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on September 29, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports stock sales for tax purposes under a pre-existing trading plan, which is a routine event.

Industry Context

Insider sales are a common occurrence, especially when related to tax obligations from vesting equity. It's important to consider the overall insider sentiment and trading patterns to gauge management's confidence in the company's future prospects.

Stakeholder Impact

• The stock sales could have a minor negative impact on shareholders due to slight dilution and potential downward pressure on the stock price, although the impact is likely minimal given the relatively small volume of shares sold.

Key Dates